Drugs in development for social anxiety disorder: More to social anxiety than meets the SSRI

Expert Opinion on Investigational Drugs

Volumn 9, Issue 10, 2000, Pages 2215-2231

  Van Ameringen, M ^a   Mancini, C ^a   Farvolden, P ^a   Oakman, J ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Agonists; Antagonists; Benzodiazepines; CCK; CRF; Dopamine; GABA; Glutamate; Monoamine oxidase inhibitors; Neuropeptides; Psychopharmacology; Serotonin blockers; Serotonin re uptake inhibitors; Social anxiety disorder; Social phobia; Substance P; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPRAZOLAM; BENZODIAZEPINE; BUSPIRONE; CLONAZEPAM; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DOPAMINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PAROXETINE; PHENELZINE; PLACEBO; PREGABALIN; PROPRANOLOL; RELEASING FACTOR; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUBSTANCE P ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ACADEMIC ACHIEVEMENT; ANXIETY NEUROSIS; COMORBIDITY; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; FEAR; HORMONAL REGULATION; HUMAN; HYPERTENSION; JOB PERFORMANCE; MENTAL DISEASE; NEUROBIOLOGY; NEUROCHEMISTRY; PREVALENCE; REVIEW; SEROTONINERGIC SYSTEM; SOCIAL DISABILITY; SOCIAL PHOBIA; SOCIAL PROBLEM; SYMPTOMATOLOGY; WORK DISABILITY;

EID: 0033772519     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.10.2215     Document Type: Review

References (176)

1. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the national comorbidity survey
2. Social phobia: Comorbidity and morbidity in an epidemiologic sample
3. Social phobia: Review of a neglected anxiety disorder
4. The prevalence of school dropouts in an anxiety disorders clinic
5. Cognitive behavioural treatments: Literature review
6. Meta-analysis of cognitive-behavioural treatments for social phobia
7. Cognitive-behavioural and pharmacological treatments of social phobia: A controlled study
8. Phenelzine vs. atenolol in social phobia: A placebo controlled trial
9. Cognitive behavioral group therapy vs. phenelzine therapy for social phobia: 12 week outcome
10. Pharmacotherapy of social phobia: A controlled study with moclobemide and phenelzine
11. Placebo controlled trial of moclobemide in social phobia
12. Moclobemide in social phobia: A controlled dose-response trial
13. Social phobia: The clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaramine. A double-blind placebo-controlled study
14. Psychopharmacological treatment of social phobia: Clinical and biochemical effects of brofaramine a selective MOA-A inhibitor
15. Brofaramine for social phobia: A multicenter, placebo-controlled, double-blind study
16. Treatment of social phobia with clonazepam and placebo
17. Psychopharmacological treatment of social phobia: A double-blind placebo controlled study with fluvoxamine
18. Fluvoxamine in the treatment of social phobia: A double-blind, placebo-controlled study
19. Sertraline for social phobia: A double-blind, placebo-controlled crossover study
20. A placebo-controlled study of sertraline in generalized social phobia
21. Treatment of generalized social phobia
22. Paroxetine in the treatment of generalized social phobia (social anxiety disorder)
23. Paroxetine in social phobia/social anxiety disorder
24. Paroxetine in the treatment of social anxiety disorder (social phobia): An overview
25. Paroxetine in social anxiety disorder: A randomized placebo-controlled study
26. The assessment and treatment of performance anxiety in musicians
27. Clinical effects of buspirone in social phobia: A double-blind placebo-controlled study
28. Imipramine in the treatment of social phobia: A double blind study
29. The treatment of social phobia: Real-life rehearsal with non-professional therapists
30. Social phobia: A comparison of behavior therapy and atenolol
31. 3 antagonist, ondansetron, in social phobia
32. Treatment of social phobia with gabapentin: A placebo-controlled study
33. A placebo-controlled study of pregabalin in the treatment of social phobia
34. Nefazodone in the treatment of social phobia
35. Nefazodone for social phobia: A clinical case series
36. 2 antagonist nefazodone
37. Venlafaxine in social phobia: A case series
38. Venlafaxine in social phobia
39. Clinical effects of venlafaxine in social phobia
40. Venlafaxine in social phobia: A study in selective serotonin reuptake inhibitor non-responders
41. Treatment of social phobia with bupropion
42. Treatment of social phobia with clonidine
43. Mirtazapine in social phobia
44. Specificity of lactate infusions in social phobia versus panic disorders
45. Lactate response to caffeine in panic disorder; a replication using an 'anxious control group'
46. High-dose carbon dioxide challenge test in anxiety disorder patients
47. Diagnostic and substance specificity of carbon dioxide induced panic
48. The 35% carbon dioxide challenge test in patients with social phobia
49. CCK
50. Anxiety and growth disturbance; is there a connection? A review of biological studies in social phobia
51. Flumazenil challenge in social phobia
52. 3H paroxetine binding to platelets of patients with social phobia; comparison to patients with panic disorder and healthy volunteers
53. Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia
54. School avoidance and social phobia triggered by haloperdidol in patients with Tourette's syndrome
55. Anxiety and Parkinson's disease
56. CSF dopamine levels correlate with extraversion in depressed patients
57. Plasma and CSF HVA levels in panic patients with comorbid social phobia
58. Responses of generalized and discrete social phobics during public speaking
59. Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders: Comparison of patients with panic disorder and social phobia and normal control subjects
60. Autonomic responsivity in generalized social phobia
61. Abnormal cardiovascular responses to standing in panic disorder and social phobia. BAP summer meeting. Cambridge
62. Growth hormone response to IV clonidine in social phobia; comparison to patients with panic disorder and healthy volunteers
63. Magnetic resonance imaging in social phobia
64. Magnetic resonance spectroscopy in social phobia: Preliminary findings
65. A repeat proton magnetic resonance spectroscopy study in social phobia
66. A brain single photon-emission computed tomography (SPECT) study of generalized social phobia
67. Dopamine reuptake site densities in patients with social phobia
68. 2 receptor binding potential in social phobia
69. Normal urinary free cortisol and postdexamethasone cortisol in social phobia
70. Levels of urinary free cortisol in social phobia
71. The hypothalmic-pituitary-thyroid axis in social phobia
72. Effects of TRH on blood pressure and heart rate in social phobia patients, panic disorder patients and normal controls; results of a pilot study
73. Neural correlates of anxiety provocation in social phobia
74. 2 antagonist nefazodone
75. MRI reveals amygdala activation to human faces in social phobics
76. Role of 5-HT in stress, anxiety and depression
77. Stability of interindividual differences in serotonin function and its relationship to severe aggression and competent social behavior in rhesus macaque females
78. Serotonergic influences on the social behavior of vervet monkeys (Cercopithecus aethiops sabaeus)
79. Dominant social status facilitates the behavioral effects of serotonergic agonists
80. CSF 5-HIAA and aggression in female macaque monkeys: Species and interindividual differences
81. Selective alteration of personality and social behavior by serotonergic intervention
82. The neurobiology of anxiety disorders: Brain circuits in panic disorder
83. 2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography
84. A computational approach to prefrontal cortex, cognitive control and schizophrenia: Recent developments and current challenges
85. Dopamine and the structure of personality: Relation of agonist-induced dopamine activity to positive emotionality
86. A computational role for dopamine delivery in human decision-making
87. A predictive reinforcement model of dopamine neurons for learning approach behavior
88. Hedonic valence, dopamine and motivation
89. Predictive reward signal of dopamine neurons
90. Role of norepinephrine in the pathophysiology and treatment of mood disorders
91. From normal fear to pathological anxiety
92. Behavioral and neuroendocrine responses in shy children
93. The noradrenergic system in pathological anxiety: A focus on panic with relevance to generalized anxiety and phobias
94. Descriptive psychopathology of social phobia
95. Shyness as a final common pathway for two different kinds of inhibition
96. Development of inhibition during childhood: Evidence for situational specificity and a two-factor model
97. Abnormal shyness in children
98. Two kinds of shyness
99. Temperament: Early developing personality traits
100. The emotional brain
101. The concept of behavioral inhibition to the familiar
102. Social anxiety, evolution and self-presentation: An interdisciplinary perspective
103. The genetics and psychobiology of the seven-factor model of personality
104. The neuropsychology of anxiety
105. 5-HT and mechanisms of defense
106. Harm avoidance and serotonin
107. Beyond the serotonin reuptake inhibitors: Rationales for the development of new serotonergic agents
108. The shyness spectrum
109. Behavioral, neuroendocrine and serotonergic consequences of single social defeat and repeated fluoxetine pretreatment in the Lewis rat strain
110. Challenges in the treatment of social phobia
111. Classical antidepressants, serotonin selective reuptake inhibitors and noradrenergic reuptake inhibitors
112. SSRIs and SMRIs: Broad spectrum of efficacy beyond major depression
113. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia
114. BASF to merge boots pharma under knoll name
115. Effect of acute administration of the 5-HT(1A)receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover
116. Profile of action of a ovel 5-Hydroxytryptamine1A receptor ligand E-4424 to inhibit aversive behaviour in the mouse, rat and marmoset
117. Neurotic inhibition and transnosographic approach. Apropos of a multicenter study of carpipramine
118. Drug development pipeline: Irbesartan, clopidogrel, SR-90107, dronedarone, oxaliplatin, tirapazamine, rasuricase, xaliprodene, eplivansein, SR-31742, SR-90067, SR-58611, SR-48968, lintitript, SR-12187, SR-121463, SR-32701, SR-142948, osanetant, SR-141716, SR-48692, SR-144190, nolpitanium besilate, SR-146131, SR-34006
119. Egis' Tensiomin tops Hungarian sales
120. Hoechst Marion Roussel announces second quarter results
121. The role of 5-HT(2C) receptors in affective disorders
122. 3 receptor antagonists. Clinical pharmacology and therapeutic applications
123. Treatment of social phobia with the dopamine agonist pergolide
124. Review of quetiapine and its clinical applications in schizophrenia
125. 2dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men
126. Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine study group
127. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?
128. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder
129. Two faces of cholecystokinin: Anxiety and schizophrenia
130. Cholecystokinin in anxiety
131. Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls
132. Anxiolytic profile of the cholecystokinin antagonist devazepide in mice
133. A double-blind, placebo-controlled study of a CCKB receptor antagonist, CI-988, in patients with generalized anxiety disorder
134. A placebo-controlled trial of L-365,260 a CCKB antagonist, in panic disorder
135. Lack of efficacy of a cholecystokinin-B antagonist in anxiety disorders
136. Effects of corticotropin-releasing factor on brain serotonergic activity
137. Corticotrophin-releasing factor receptor antagonists
138. CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors
139. Neurocrine announces that Janssen Pharmaceutical intends to replace R121919 with a back-up compound - Neurocrine CRF program on track for Phase I trials to begin 2nd half 2000 with unpartnered CRF antagonist for anxiety/depression
140. Neurocrine announces its financial results for the year ended December 31, 1998
141. Neuropeptide Y - A novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide
142. Neuropeptide Y: Anatomical distribution and possible function in mammalian nervous system
143. Elevated plasma levels of neuropeptide Y in patients with panic disorder
144. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively
145. Plasma neuropeptide Y in anxiety disorders: Findings in panic disorder and social phobia
146. 1 receptor in the brain: Pharmacology and putative functions
147. Receptors and antagonists for substance P and related peptides
148. Neurotransmitter functions of mammalian tachykinins
149. Peptides and psychiatry part 3: Substance P and serendipity: Novel psychotropics are a possibility
150. Distinct mechanism for antidepressant activity by blockade of central substance P receptors
151. Behavioural effect of the NK2 antagonist SR 48968 but not of the NK1 antagonist SR 140333 in the mouse black and white box model
152. Behavioural effects of intracerebroven-tricular injection of selective tachykinins agonists and antagonists
153. Anxiolytic action of substance P administered systemically or into the basal forebrain
154. Anxiolytic-like effect of injecting neurokinin substance P systematically or into the basal forebrain
155. GR159897, a potent non-peptide tachykinins NK2 receptor antagonist, releases suppressed behaviours in a novel aversive environment
156. Effects of central administration of tachykinins receptor agonists and antagonists on plusmaze behaviour in mice
157. The anxiolytic-like activity of GR159897, a non peptide NK2 receptor antagonist, in rodent and primate models of anxiety
158. New anti-epileptic drugs
159. Interneuron's Pagoclone significantly reduces panic attacks in Phase 2/3 clinical trial drug achieves primary endpoint, advances in clinical development
160. Efficacy and safety of pagoclone in the treatment of panic disorder
161. Iddb meeting report
162. Drug development pipeline: Rolipram, SH-329, SH-470, SH-592, SH-543, levonorgestrel depot, Schering AG, SH-386, ZK-807191, azelaic acid, gadobutol, Sonovist, PTK-787, SH/TA-508, SH-U-555
163. Novel anxiolytics that act as partial agonists at benzodiazepine receptors
164. Glutamate receptors in the mammalian central nervous system
165. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy
166. The glycine site on the NMDA receptor: Structure-activity relationships and possible therapeutic applications
167. Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride
168. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders
169. Use of topiramate, a new anti-epileptic as a mood stabilizer
170. Kainate receptors: An interplay between excitatory and inhibitory synapses
171. Anxiolytic and side-effect profile of LY354740: A potent, highly selective orally active agonist for group II metabotropic glutamate receptors
172. Iddb meeting report
173. Iddb meeting report